



EHA2026 Congress

June 11–14, 2026
Stockholm, Sweden



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.

Thank you to the funders of the MPN Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our current funders can be found at: [MPN-Hub.com](https://www.mpn-hub.com).

EHA2026: Top abstracts in MPN

June 11–14, 2026

Oral presentations: Friday, June 12

Abstract	Title	Presenter	Time (CEST)
S210 View	Development of a G6B directed antibody drug conjugate for the treatment of myeloproliferative neoplasms	Adam Mead	17:15–17:30
S213 View	CD9 marks the disease-propagating hematopoietic stem cell population in myelofibrosis	Lara Tavernari	17:45–18:00
S214 View	Transcriptional subtypes of myelofibrosis are independent of driver mutations and capture distinct biology, outcomes, and disease trajectories	Andy Zeng	18:00–18:15

Oral presentations: Saturday, June 13

Abstract	Title	Presenter	Time (CEST)
S215 View	Efficacy and safety of luspatercept in patients with myelofibrosis on Janus kinase inhibitors who require red blood cell transfusions: Primary analysis of the phase 3 INDEPENDENCE trial	Francesco Passamonti	17:15–17:30
S216 View	Mutant calreticulin-specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients (pts) with myelofibrosis (MF)	Claire Harrison	17:30–17:45
S217 View	Efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis: Primary results from the APEX study	Daniel J. DeAngelo	17:45–18:00
S218 View	Results of AJX-101, a phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor	John Mascarenhas	18:00–18:15
S219 View	Early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythaemia: Two-year results from the phase 3 SURPASS-ET study	Harinder Gill	18:15–18:30

Oral presentations: Sunday, June 14

Abstract	Title	Presenter	Time (CEST)
LB5002 View	Selinexor plus ruxolitinib in Janus kinase inhibitor-naïve myelofibrosis: Phase 3 sentry trial	Claire Harrison	09:30–09:45

Posters

Abstract	Title	Presenter	Date and time (CEST)
PF886 View	Divesiran, a novel GalNAc conjugated siRNA, reduces phlebotomies, improves iron stores and symptoms in polycythemia vera patients in SANRECO phase 1 study	Marina Kremyanskaya	Friday, June 12, from 18:45
PF890 View	Thromboembolic and progression events in phlebotomy-dependent patients with polycythemia vera (PV): Long-term results from the phase 2 REVIVE and THRIVE open-label extension rusfertide studies	Naveen Pemmaraju	Friday, June 12, from 18:45
PF891 View	Effect of rusfertide on cytoreductive therapy use in patients with phlebotomy dependent polycythemia vera: <i>Post hoc</i> analysis from the randomized controlled phase 3 VERIFY study	Francesca Palandri	Friday, June 12, from 18:45
PF894 View	Evaluation of pelabresib (PELA) as add-on therapy to Janus kinase inhibitor (JAKi) ruxolitinib (RUX) in myelofibrosis (MF) patients: Results from Arm 2 of the open-label, phase 2 MANIFEST study	Marina Kremyanskaya	Friday, June 12, from 18:45
PF909 View	RESTORE-PV – A phase 2 open-label study evaluating the safety and efficacy of the anti-TMPRSS6 monoclonal antibody DISC-3405 in participants with polycythemia vera	Naseema Gangat	Friday, June 12, from 18:45
PF912 View	Hematologic control and improved safety following crossover from anagrelide to ropeginterferon alfa-2b in patients with essential thrombocythemia: Data from the SURPASS-ET study	Lucia Masarova	Friday, June 12, from 18:45
PS1983 View	Mutant calreticulin-specific monoclonal antibody, INCA033989, is well tolerated and achieves rapid and sustained hematologic and molecular responses in patients with essential thrombocythemia (ET)	John Mascarenhas	Saturday, June 13, from 18:45
PS1984 View	Fedratinib + nivolumab combination improves outcomes in myelofibrosis patients resistant or suboptimally responding to JAK-inhibitor therapy – Results from the FRACTION trial (IKF051)	Susanne Isfort	Saturday, June 13, from 18:45
PS1985 View	Investigational PIM1 inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Data from an ongoing global phase 1/2 study	James McCloskey	Saturday, June 13, from 18:45
PS1986 View	Rpeginterferon alfa-2b demonstrates molecular and hematologic responses with a favorable safety profile in essential thrombocythemia	Harinder Gill	Saturday, June 13, from 18:45
PS1987 View	Pelabresib monotherapy in myelofibrosis after Janus kinase inhibitor failure: Results from Arm 1 of the open-label, phase 2 MANIFEST study	Moshe Talpaz	Saturday, June 13, from 18:45

Posters (continued)

Abstract	Title	Presenter	Date and time (CEST)
PS1995 View	Outcomes with momelotinib in patients with intermediate-1- vs intermediate-2-/high-risk myelofibrosis: <i>Post hoc</i> analyses of the phase 3 SIMPLIFY-1 and MOMENTUM trials	Prithviraj Bose	Saturday, June 13, from 18:45
PS1997 View	Update from the phase 2 RESTORE trial of elritercept in patients with myelofibrosis (MF) receiving ruxolitinib	Ciro Rinaldi	Saturday, June 13, from 18:45
PS2002 View	Dynamic cytopenia patterns in myelofibrosis: A real-world analysis from the ERNEST-3 registry	Tiziano Barbui	Saturday, June 13, from 18:45
PS2005 View	SHORESPAN-017: A phase 3 extension study evaluating the safety of continued bomedemstat in participants with essential thrombocythemia	Francesca Palandri	Saturday, June 13, from 18:45
PS2010 View	Consistency of response by baseline platelet count in pacritinib-treated patients in the real world: MY-PAC analysis	James Rossetti	Saturday, June 13, from 18:45
PS2013 View	Analysis of variant allele frequency of <i>JAK2V617F</i> in patients with polycythemia vera treated with either ruxolitinib or best available therapy in the randomized phase 2b RUXOBEAT clinical trial	Madeline Caduc	Saturday, June 13, from 18:45



#EHA2026

Follow us on X to keep up to date
with the latest from the congress

@MPN_Hub



Brought to you by

